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ABSTRACT: Raman spectroscopy (RS) has shown promise
as a tool to reveal biochemical changes that occur in cancer
processes at the cellular level. However, when analyzing
clinical samples, RS requires improvements to be able to
resolve biological components from the spectra. We compared
the strengths of Multivariate Curve Resolution (MCR) versus
Principal Component Analysis (PCA) to deconvolve mean-
ingful biological components formed by distinct mixtures of
biological molecules from a set of mixed spectra. We exploited
the ﬂexibility of the MCR algorithm to easily accommodate
diﬀerent initial estimates and constraints. We demonstrate the
ability of MCR to resolve undesired background signals from
the RS that can be subtracted to obtain clearer cancer cell
spectra. We used two triple negative breast cancer cell lines, MDA-MB 231 and MDA-MB 435, to illustrate the insights obtained
by RS that infer the metabolic changes required for metastasis progression. Our results show that increased levels of amino acids
and lower levels of mitochondrial signals are attributes of bone metastatic cells, whereas lung metastasis tropism is characterized
by high lipid and mitochondria levels. Therefore, we propose a method based on the MCR algorithm to achieve unique
biochemical insights into the molecular progression of cancer cells using RS.
Metastatic cancer cells are characterized by reprogram-ming of the cellular metabolism that leads to increased
uptake of glucose for use as an anabolic and catabolic substrate,
thus satisfying the increased demands for macromolecules and
energy for proliferation.1 Recent investigations into the
mechanisms that underlie the Warburg eﬀect, also known as
aerobic glycolysis, suggested that mitochondrial uncoupling can
promote aerobic glycolysis, which may represent a shift to the
oxidative metabolism of nonglucose carbon sources.2 Under-
standing and analyzing mitochondrial uncoupling and the
metabolic changes observed in cancer cells are important
because they may be associated with increased resistance to
chemotherapeutic insults.3 Moreover, increased mitochondrial
oxidative metabolism may be a key driver of tumor cell
metastasis.4
We have previously studied the biochemical characteristics of
breast cancer metastatic cells by Raman spectroscopy (RS),5 a
technique based on the inelastic dispersion of monochromatic
radiation that provides speciﬁc vibrational signatures of
chemical bonds and therefore can be used to determine the
chemical composition of cells.6 RS has been used in the past
decade to study biological samples with the help of statistical
analysis. Various techniques have been used to ﬁnd groups and
clusters in the RS data set, such as Principal Component
Analysis (PCA),5,7,8, K-means clustering,9,10 and Neural
networks.11 Partial-Least-Squares Discriminant Analysis (PLS-
DA) allows the construction of discriminatory models to
distinguish diﬀerent types of samples and thus it has been used
to diﬀerentiate breast cancer metastatic cells from non-
metastatic cells without a basal-like phenotype.5 Two-dimen-
sional correlation has been used to gain insights into the Raman
bands and band evolution such as broadening, shifts, and so
on12 to study dynamic processes. However, the multivariate
techniques mentioned above do not provide suﬃcient
information to extract the molecular picture of the process
being analyzed and thus do not exploit all the capabilities of RS.
Unmixing techniques such as Vertex Component Analysis
(VCA)10,13,14 has been used to analyze Raman spectral data in
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an eﬀort to resolve more “pure” signals. Although VCA and N-
FINDR have been often used, these algorithms assume the
presence of “pure” pixels in the data set (which in the case of
Raman spectra of biomedical samples is very complicated due
to the highly mixed molecular content present). Second, they
need to use necessarily non-negativity and closure constrains to
work, which is not always possible if Raman spectra are
transformed, for example, into derivative spectra, or when pixel-
to-pixel high variations of total signal exist. Within the group of
unmixing algorithms, Multivariate Curve Resolution-Alternat-
ing Least Squares (MCR-ALS), is a very ﬂexible algorithm in
which many constraints can be easily included, like non-
negativity, selectivity, or local rank,15,25 information on
presence/absence of components in diﬀerent data blocks in
multiset structures (so-called correspondence among spe-
cies22). However, all constraints can be optionally applied in
MCR and none of them is compulsory. In this paper, we used
non-negativity in the concentration and spectral direction and
the selectivity constraint linked to spectra of background
contributions in the MCR algorithm in order to resolve more
easily meaningful spectral proﬁles of biological components
from the mixed Raman spectra of cancer cells.
There are various drawbacks that need to be overcome to
fully exploit RS for diagnostic purposes.12,16 First, cells are
grown on the surface of glass materials and the focus of the
laser needs to be close to or past the surface window. Thus, part
of the confocal volume analyzed includes a portion of the glass,
which consequently produces undesired background signals in
the RS. Second, samples contain stains and are prepared on
coverslips that give a very high signal and disturb the inherent
cellular RS. Bonnier et al.17 tried to remove the eﬀect of the
background signals in the spectra by growing the cells in
collagen matrices on the top of coverslips but this requires
sample processing and modiﬁcation of already established
biomedical protocols. Finally, in applications for in vivo RS
analysis which involve ﬁber optical probes, high background
signals from silica perturb the Raman spectra and consequently
reduce the ability to perform stable and robust statistical
models. Therefore, further development is essential to reduce
background spectral signals in these cases.18−20
In this study, we present a powerful statistical methodology
to remove undesired background signals and extract meaningful
molecular components from Raman spectra. The method is
based on the use of MCR-ALS, a very ﬂexible and powerful
algorithm that has been applied to several chemical problems21
Recently, it has been applied to biomedical RS data.22−25
Speciﬁcally, we ﬁrst compared the ability of PCA and MCR
analysis applied to the same RS data to resolve molecular
spectral contributions. Second, the use of the ﬂexibility of the
MCR-ALS algorithm was used to include speciﬁc constrains
(non-negativity and selectivity constraint) to extract the quartz
and water background signal from the spectral data and remove
it from the RS. Both procedures have been used to gain insights
into the metabolic changes that breast cancer cells undergo
while progressing with diﬀerent metastasis tropisms.26
We used two triple negative human breast cancer cell lines,
MDA-MB-231 and its osteotropic cell line B02 subclone and
MDA-MB-435 (435P) with tropism to metastasize in the lung
and its bone metastatic variant 435-B. We carried out RS and
MCR-ALS analysis to study biochemical diﬀerences between
metastasis tropisms. The results showed that an increase in
amino acids and a decrease in mitochondrial signals were
attributes of bone metastatic cells, whereas lung metastasis
tropism was characterized by high lipid and mitochondria
(cytochrome C and RNA) levels. We demonstrate that RS
coupled with the MR-ALS algorithm resolve meaningful
molecular components during metastatic progression of cancer
cells, giving more biochemical information than other
commonly used mathematical techniques. Furthermore, we
propose exploiting the ﬂexibility of the MCR-ALS algorithm to
enhance and expand the strengths of RS for clinical diagnosis,
and demonstrate the successful subtraction of undesired
background signals (that are unavoidable in clinical practice),
allowing the extraction of more valuable information from RS.
■ MATERIALS AND METHODS
Cell Lines Used.We used the breast cancer bone metastatic
cell line MDA-MB-231 (231P), originally obtained from the
European Type Culture Collection (ECACC 92020424), and
B02 (kindly provided by Philippe Clezardin, INSERM, UMR
664, IFR62, Laennec School of Medicine, F-69372, Lyon,
France) established from bone metastases caused by MDA-MB-
231 after six in vivo/in vitro passages in nude mice using a heart
injection model.27 The proprietary 435-B cells were obtained
from primary cultures of bone metastasis induced by MDA-MB
435 (435P) cells inoculated in the intramammary fat path.28
The proprietary B02/PRDX2 cells29−31 were previously
obtained from highly bone metastatic BO2/GFP cells over-
expressing PRDX2 (BO2/PRDX2) through the pBIL vector
system.
Cells were cultured under standard conditions in DMEM/
F12 medium supplemented with 5% horse serum, 1 mM
pyruvate, 2 mM L-glutamine in 5% CO2−95% air at 37 °C in a
humidiﬁed incubator.
Raman Spectroscopy (RS). For RS analysis 3 × 105 cells
were used and measurements were carried out by seeding cells
over a quartz crystal (ESCO products, Oak Ridge, NJ) in six-
well plates (Becton Dickinson, NJ). After 24 h, cells were ﬁxed
with 4% cold paraformaldehyde (PFA) in PBS 1× for 15 min,
washed with PBS 1× and maintained in the same solution at 4
°C until the spectroscopic analysis.
A total of 225 spectra were obtained from the cell cytoplasm
(few μm away from the nucleous, see the inset in Figure 2b)
from both the parental cell lines and their corresponding
metastatic variants.
The Raman system used was an inVia Renishaw (Apply
Innovation, Gloucestershire, U.K.) and comprises a 532 nm
laser that supplies an excitation beam of about 10 mW power,
which is focused onto the sample via a microscope with a 60×
objective (Edmund, York, U.K.) using a backscattered
conﬁguration. The laser spot size in the sample is 0.8 μm.
The Raman spectrum is recorded on a deep depletion charge-
coupled device (CCD) detector (Renishaw RenCam). The
recorded Raman spectrum is digitalized and displayed on a
personal computer using Renishaw WiRE software, which
allows the experimental parameters to be set. The spectra were
background subtracted with a custom-written Labview program
using an established method.32
Statistical Analysis. First, an exploration of the spectral
data set was performed using PCA. The number of components
selected was the number in which the cumulative variance
explained was more than 99%. Two independent analyses
(PCA and MCR) were performed on the same data set, which
contained the spectra of the cell lines in rows. Additionally, to
improve background component resolution ﬁve spectra from
the PBS solution on the same quartz substrate and at the same
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focal distance as the cell measurements and far away from the
cells were added. These spectra were used to include selectivity
constraints to the MCR algorithm indicating the presence/
absence of molecular components in some of the measured
spectra. For the MCR-ALS algorithm, the protocol followed
was: ﬁrst, the initial estimates were selected using a purest
variable selection method algorithm, which selects the purest
rows (spectra) in the data set; second, the iterative least-squares
calculation started with the addition of constraints (non-
negativity of spectra and concentration matrices and selectivity
constraint for concentrations linked to spectra with only
background contributions). Finally, the quality parameters from
the MCR model were calculated: Lack of ﬁt:
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where ei,j = di,j − d ̂i,j and di,j is the original data matrix and dî,j is
calculated by means of the MCR-ALS algorithm.
For PCA and MCR analysis two diﬀerent Matlab toolboxes
were used: PLS toolbox (from eigenvector Research) and
MCR-ALS toolbox (from University of Barcelona).
■ RESULTS AND DISCUSSION
Multivariate Curve Resolution-Alternating Least
Squares (MCR-ALS) is Able to Resolve More Meaningful
Molecular Components than Principal Component
Analysis (PCA) on Raman Spectra (RS). First, a PCA was
performed on the spectral data matrix containing 135 spectra
from the cytoplasm area (avoiding the nucelous) of 231, B02,
435, and 435-B cells and ﬁve more from PBS, from which the
principal component loadings were plotted (Figure 1A). These
results were compared with those obtained from the MCR-ALS
algorithm subjected to speciﬁc constraints (non-negativity of
spectra and concentrations, and selectivity constraint) (Figure
1B,C) and applied to the same spectral data set. We
demonstrated that when using MCR-ALS more chemically
meaningful molecular components are extracted. Furthermore,
we were able to separately resolve two components containing
quartz and water signals.
The results of PCA (Figure 1A) showed that the signals of
diﬀerent substrates were mixed in among the loadings of the
principal components. The contributions of quartz signal17,33
(mainly bands around 800 and 1050 cm−1) were found in PC3,
together with water signal and other cellular substrates. Indeed,
the presence of positive and negative bands in the principal
component loadings made the assignment of each component
to a molecular RS contribution diﬃcult. In contrast, MCR
decomposed four meaningful components (Figure 1B) that
could be assigned to cellular lipids (component 1), quartz
signal (component 2), water signal31 (component 3) and
proteins and other cellular components (component 4). The
variance explained by PCA and MCR models was 99.74% and
99.66%, respectively.
MCR spectra provided more chemically meaningful results
than PCA, providing two components, 2 (quartz) and 3
(water), that did not correspond to cellular molecular
components.17,33,34 Indeed, the higher ability of MCR to
resolve pure signals relied on the ﬂexibility of the MCR-ALS
algorithm. First, the spectral data matrix was constructed by
displaying all cell RS in rows and adding ﬁve more rows
containing the signal from PBS, acquired at the same focal
distance as for the cells on the quartz substrate. Second, a
purest variable selection algorithm was used to ﬁnd the purest
spectra in the data set in order to provide initial estimates of the
MCR-ALS algorithm. As a result, the four most dissimilar
spectra found were two signals from PBS solution and two from
diﬀerent cell lines. Once the initial estimates were selected, the
iterative least-squares calculation was initialized by placing
constraints on the algorithm. First, we included non-negativity
in the resolved spectra and concentration proﬁles. Second, a
matrix showing the presence/absence of molecular components
Figure 1. MCR-ALS analysis gives more chemically meaningful
components than PCA. PCA (A) and MCR-ALS (B) loadings of the
matrix spectral data set containing the Raman spectra (RS) obtained
from the cytoplasm of cancer cell lines 231P, B02, 435P and 435B, and
PBS. (C) MCR-ALS constraints were applied to the data: non-
negativity and selectivity constraint to resolve quartz and PBS spectra.
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such as water, quartz and cellular spectra was encoded (Figure
1c). In the rows where there was absence of cellular spectra,
zeros were included to the components from quartz and water
that we wanted to resolve. The above process yielded four
chemically and physically meaningful components.
Unlike MCR, PCA found the orthogonal directions in the
data set with the maximum variance, but no additional chemical
information could be added. Consequently, in the case of
complicated biological Raman data sets, PCA could be used for
an exploratory analysis of the data set to ﬁnd, for instance,
outliers or groups or to understand the chemical structure of
the data as a ﬁrst approach, but not meaningful molecular
spectral components can be unmixed using this method. This
problem has been mentioned in previous cellular studies35 and
in studies involving image segmentation.33
Subtraction of the Background Signals by MCR
Allowed the Resolution of Metabolites in Metastatic
Breast Cancer Cells. In order to clean and remove quartz and
water signals from the original spectral data set, direct
subtraction of both signals (MCR loadings) multiplied by the
concentration matrix (MCR scores) of those components for
each original spectrum was performed. This led to greater
visibility of some spectral changes inherent to the cellular
spectra, making it easier to build a statistical model with
chemically meaningful outputs. The results are shown in Figure
2, where the plots of spectra before (Figure 2A) and after
(Figure 2B) the subtraction of quartz and water signals are
compared. Furthermore, by using this method, statistical
analysis of cell RS is improved as long as the background is
removed. Thus, based on the clean cell RS, a new MCR model
was calculated to resolve pure molecular RS involved in the
diﬀerent biochemical components of metastatic progression
(Figure 3).
Recently, various applications of MCR to Raman images have
detected the contribution of background signals in the resolved
components.36−39 However, to our knowledge, this is the ﬁrst
time that the MCR-ALS algorithm has been proposed as a tool
to subtract the background signal contributions in the Raman
analysis of cells when using standard sample preparation. For
clinical relevancy and acceptance of RS by the clinical
community, it is important that the sample preparation
protocols necessary for RS are coincident with current practice.
Nowadays this is a challenging issue and researchers are
working to overcome this limitation. For instance, a study
compared Raman signals of unprocessed tissue preparations
and dewaxed tissue sections, demonstrating that tissue
processing has a signiﬁcant impact on the extracellular
structure, in particular on the lipidic structure.40 Also, in the
clinical applications of RS related with endoscopy, background
signals due to the use of ﬁber optics have been reported as one
of the main issues.41,19 Furthermore, the use of routine stained
tissue sections or cells for RS analysis has been limited due to
background signals that interfere with the Raman spectra.42
Therefore, to prevent the loss of critical cellular information, RS
should be compatible, as much as possible, with conventional
sample preparation, without the need for further processing.
This challenge might be overcome by resolving noninherent
signals from current cytological preparations from the cell
spectra. In this way, everyday techniques could be performed in
parallel with Raman spectroscopy analysis using the same
samples. Moreover, the use of stored samples might permit
retrospective studies based on prognosis and patient follow-up.
It is important to note that from a matrix with very similar
cell RS the MCR-ALS algorithm permitted the resolution of
three meaningful molecular components. Indeed, RS were
assigned to almost pure molecules. Therefore, this analytical
method extracted more biochemical information than other
commonly used techniques, such as PCA or cluster analysis,
providing information about the biochemical changes occurring
in metastatic cancer cells (Figure 3). The concentrations of
each MCR component for each cell variant measured were
plotted (Figure 3, right) with their corresponding spectra
(Figure 3, left). In particular, component 1 was assigned to cell
lipids.43 Raman bands in component 2 have been related to
amino acids and cell proteins.44,45 Finally, component 3
contained bands previously assigned to mitochondria, contain-
ing bands from cytochrome C46−54 and DNA or nucleotides.55
As mitochondria are the organelles in the cytoplasm that
contain the highest concentrations of DNA and cytochrome C,
this led to the conclusion that component 3 could be used as a
measure of the number of mitochondria present in breast
cancer metastatic cells. Table 1 shows the main assignments of
Raman bands from each component.
When comparing the three main biochemical components
that diﬀerentiate cells, we observed that component 1, assigned
to cell lipids, was inversely proportional to capacity for bone
metastasis such that its value decreased as long as the bone
Figure 2. Subtraction of background signals in cellular RS using MCR-
ALS algorithm: RS before (A) and after the subtraction of quartz and
water signals (B). MCR loadings from Figure 1B were used to resolve
the meaningful molecular contributions. The ﬁgure inset in (B) shows
an image of a MDA-MB-231 cell, indicating with green arrows the
areas in which the Raman spectra was obtained. Raman image is
showing the lipid distribution (component 1) in the cytoplasm of the
cell.
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tropism increased. This is in agreement with the described
“low-lipid” phenotype that characterized breast cancer cells
compared with normal breast epithelial cells, and negatively
correlated with invasiveness and metastatic progression.56 The
lowest level of component 1 was found in B02 cells and the
highest level was found in 435P cells, which showed the
greatest lung metastatic tropism. Moreover, we were able to
distinguish two diﬀerent populations belonging to 435P cells,
Figure 3. Using MCR-ALS analysis of Raman spectra from 231P, B02, 435P, and 435B cell lines to delineate bone metastasis ability. An improved
MCR-ALS model was built using RS after the subtraction of quartz and water signals. Three components were resolved and their respective MCR
loadings (left) and scores (right) are plotted: red triangles, B02; blue squares, 231P; blue crosses, 435B; and white diamonds, 435P. Components 1
(A), 2 (B), and 3 (C) have bands compatible with cellular lipids, amino acids, and mitochondria-related molecules, respectively. The variance
explained for each component is shown as a %.
Table 1. Raman Spectra Band Assignments of MCR Components Obtained from the MCR-ALS Analysis in Figure 3a
component 1 component 2 component 3
band
(cm−1) assignment
band
(cm−1) assignment
band
(cm−1) assignment
836 saccharide 693 amino acid methionine 750 cytochrome C
1057 triacylglycerols 710 amino acid methionine 777 cytosine, thymine
1075 triacylglycerols 822 C−C stretch 804 phosphoric acid
1119 triacylglycerols 997 phenylalanine 996 phenylalanine
1260 fatty acid, cholesterol, triacylglycerols, membrane
lipids
1026 phenylalanine 1082 phospholipids, nucleic acid
1295 fatty acid 1082 glutamic acid 1120 cytochrome C
1442 fatty acid, cholesterol 1122 C−N proteins 1203 nucleic acid
1660 unsaturated fatty acid 1201 trypt, aromatic C−N, and amide III 1240 RNA
1263 amide III 1312 cytochrome C
1293 alanine 1333 adenine, guanine
1336 C−H, amide III, Trypt, glycine 1445
1442 CH2 1570 cytochrome C,
mitochondria
1654 amide I 1585 cytochrome C,
mitochondria
aAssignments based on refs 43−55.
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one with lower lipid content that was clearly enriched in the
435-B bone metastatic variant (Figure 3A). These clear
diﬀerences in lipid level between the two triple negative
(231P and 435P) breast cancer metastatic cell lines might be
due to the lung metastatic background that characterizes 435P
cells, in contrast to 231P cells that have greater bone metastatic
ability. Therefore, the low fat content is associated with bone
metastatic ability.
Component 2, which was assigned to protein content,
increased in parallel with increasing bone metastasis tropism.
The lowest level of component 2 was found in 435P cells, and
the highest level was found in the B02 bone metastatic variant.
Moreover, 435-B had a higher amino acid content than 435P
(Figure 3B).
Component 3, which contain bands from cytochrome C46−54
and DNA or nucleotide bands,55 was inversely related to bone
metastatic ability. Thus, similarly to lipid content, scores in
Component 3 increased in 435P cells with regard to bone
metastatic ones (Figure 3C). In summary, the MCR-ALS
algorithm applied to a set of cytological RS provided insights
into the subtle metabolic changes that breast cancer cells
undergo on the path toward bone metastasis tropism, as
revealed by the diﬀerent proﬁles obtained in the analysis of
231P cells, with tropism to metastasize in bone, and 435P, with
tropism to metastasize in lung. Moreover, the respective bone
metastatic variants, B02 and 435-B, were classiﬁed according to
their corresponding phenotype. These results are consistent
with reports demonstrating that the mechanism used to cope
with the cumulative reactive oxygen species diﬀers between
lung and bone tissues, with the lower oxygen gradient in bone
marrow inducing fewer metabolic free radical challenges.54
Mitochondria are an important cell metabolic hub because
they orchestrate the biosynthesis of lipids, proteins, and nucleic
acids and maintain redox homeostasis via the generation of
NADH and NADPH.57 Although in normal cells the TCA
cycle is mostly involved in glucose oxidation, the mitochondrial
metabolism of cancer cells is generally uncoupled from
glycolysis.58 It has been reported that mitochondrial glucose
oxidation may be incompatible with the survival of some cancer
cells.59 Due to genetic and environmental cues, such as hypoxia,
the enzyme responsible for the entry of glucose-derived carbons
into the mitochondria, the pyruvate dehydrogenase complex
(PDH), is frequently inactivated in cancer.60 This mechanism
might be particularly important in metastatic cells in a hypoxic
organ like bones. Furthermore, the homeostatic mechanism of
the antioxidant system might prevent collapse by redirecting
the glycolytic ﬂux into the pentose phosphate pathway.58 All
together, these results clearly indicate that a metabolic switch in
breast cancer cells might be used to ﬁt with the microenviron-
ment at the metastatic loci.
RS Supported by MCR-ALS Algorithm Dissects
Metabolic Functions of Metastatic Breast Cancer Cells.
Since breast cancer bone metastatic cells might be characterized
by a clear increase in protein content and a lower lipid content
Figure 4. MCR analysis of Raman spectra from 231P, B02 (the high bone metastatic cell variant), and B02-PRDX2 that overexpress PRDX2 and
have low bone metastasis ability in vivo (Stresing, 2011). Three components were resolved and their respective MCR loadings (left) and scores
(right) are plotted: red triangles, B02; blue squares, 231P; green circles, B02-PRDX2. Components 1 (A), 2 (B), and 3 (C) have bands compatible
with cellular lipids, amino acids, and mitochondria-related molecules, respectively. The variance explained for each component is shown as a %.
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than other breast cancer cells, we analyzed B02 cells
overexpressing PRDX2 (B02/PRDX2 cells) that exhibited a
low bone metastatic burden in vivo.29 PRDX2 is a highly
eﬃcient redox protein that neutralizes hydrogen peroxide,
resulting in protection of cells from oxidative damage and in
regulation of peroxide-mediated signal transduction events.61,62
The low metastatic burden of B02/PRDX2 cells in bones
suggests that PRDX2 might interfere in the preferential bone
metastatic cells’ metabolism with deleterious consequences for
carcinoma cells that try to adapt to the bone microenviron-
ment. This model was included in the study to better assess the
sensitivity of RS-MCR to diﬀerentiate small molecular changes
that induce important functional cell changes.
The model described above was tested in an independent
matrix containing the RS of BO2, 231P, and B02/PRDX2 cells.
First, the signals from quartz and water were subtracted
following the method described before and then an MCR was
built to conﬁrm the molecular behavior of the diﬀerent cell
lines and speciﬁcally the role of PRDX2 up-regulation Figure 4.
MCR analysis of these experiments revealed that lipid levels
were higher in B02/PRDX2 cells as reﬂected in Component 1
levels (Figure 4A) and strongly correlated with the above
observation that the lipid content of cells was inversely related
to the bone metastasis potential (Figure 4A). In fact, as
previously demonstrated,63 the preferential bone metastatic
metabolism of B02 cells can be disrupted by overexpressing
PRDX2, which induces low glucose dependence. These results
suggest a metabolic shift from glucose oxidation to fatty acid
oxidation that would resist metabolic insults in an hypoxic and
hypoglycemic tissue like bones.
Moreover, component 2 (Figure 4B; related to amino acids)
was found at lower levels in BO2/PRXD2 cells in comparison
to B02 cells, but at similar levels to those in MDA-MB-231
cells, supporting the idea that lower amino acid content is
associated with higher bone tropism. In addition, component 3
was found at higher levels in BO2/PRXD2 cells, coinciding
with the fact that cytochrome C was previously found to be
inversely associated with bone tropism, increased from BO2 to
BO2/PRXD2 cells that is not able to metastasize in bones
(Figure 4C). This is in agreement with the results shown in
Figure 3C, where we deﬁned bone metastasis tropism, and
which all together supported the biological use of MCR
applications to sensitively analyze the ﬁne biochemical changes
that occur in bone metastasis progression. Moreover, a PLS-DA
analysis to discriminate BO2 cells from MDA-MB-435P was
performed (Figure 5) that achieved a speciﬁcity of 100% and
speciﬁcity of 90%. Cross-validation was performed using 10
samples that were excluded from the data set. This corroborates
our hypothesis and highlighted that RS is able to assess and
identify bone tropism in breast cancer cells
Despite advances in treatment, 20−30% of patients with
early breast cancers will experience relapse with distant
metastatic disease.63 Triple negative tumors have the highest
metastatic rate with regard to luminal and HER2 positive
tumors, with bone and lung being the main target of breast
cancer metastasis. Transcriptomic analysis of a variety of cell
lines has identiﬁed the genes that mediate metastasis to bone or
lungs,64−66 but in clinical settings breast cancer subtyping is
based on pathological characteristics.67
With the development of metabolomics we have learnt that
metabolic variability and ﬂexibility enable tumor cell pro-
gression by generating ATP as an energy source.68 Three major
components of the metabolic transformation of cancer cells
have been described:69 aerobic glycolysis, mitochondrial
metabolism, and lipid synthesis.
We provide data demonstrating that RS coupled with the
MCR-ALS algorithm is a powerful method that can be used in a
clever and ﬂexible way to reveal the underlying molecular
information stored in RS, allowing a further step forward in the
analysis of biological RS relative to the multivariate techniques
already used to analyze metabolic changes in cancer cells.
Moreover, RS provides a unique possibility for real-time and
nonintensive-processing of tissue material for the detection of
normal, precancerous and cancerous breast tissues.70 We
propose the use of the MCR-ALS algorithm to enhance and
expand the strengths of RS for clinical diagnosis.
■ CONCLUSION
We propose a new methodology for extracting the useful
molecular information encoded in RS of biological samples. By
using the ﬂexible MCR-ALS algorithm meaningful molecular
components can be extracted, thanks to the prior subtraction of
background signals that perturb the inherent cell RS and
including speciﬁc constrains indicating the presence/absence of
molecular components. This methodology opens up new
possibilities for the clinical diagnostic use of RS, since it permits
the removal of signals from substrates or chemicals used in
cytological techniques. It also provides a rapid, reliable, and
label-free method with which to disentangle, in cancer cytology,
the biochemical components involved in metastasis progres-
sion, and as such could improve prognosis and early prevention.
We applied this methodology to study the molecular
diﬀerences between primary breast cancer cell lines and their
metastatic variants in bone. We identiﬁed biochemically
meaningful molecular components that play a role in the
metastatic ability of breast cancer cells. Speciﬁcally, the protein
component was found at higher levels whereas mitochondria
and lipids bands were found at lower levels in bone metastatic
cell variants (B02) in relation to their corresponding parental
cell lines (231P and 345P). Thus, a ratio of these three
components might be used to validate this data in clinical
samples. In addition, a PLS-DA was performed showing high
sensitivity and speciﬁcity in the discrimination of BO2 and
MDA-MB-435P cells.
Figure 5. Speciﬁcity of 100% and speciﬁcity of 90% are achieved with
the use of PLS-DA analysis to discriminate BO2 cells from MDA-MB-
435P. This corroborates that RS is able to assess and identify the bone
tropism of breast cancer cells.
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